| Date Filed | Type | Description |
| 08/21/2023 |
8-K
| Other Events Interactive Data |
| 08/09/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/01/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 11% stake in RHYTHM PHARMACEUTICALS INC |
| 05/02/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/02/2023 |
8-K
| Quarterly results|
Docs:
|
"Three months ended March 31, 2023 2022 Revenues: Product revenue, net $ 11,469 $ 1,498 Costs and expenses: Cost of sales 1,421 230 Research and development 37,945 32,510 Selling, general, and administrative 24,634 21,449 Total costs and expenses 64,000 54,189 Loss from operations Other income: Other expense, net Interest expense — Interest income 3,440 160 Total other income , net 352 Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 56,708,975 50,326,627 Other comprehensive loss: Net loss $ $ Foreign currency translation adjustment 21 — Unrealized gain , net on marketable securities 65 Comprehensive loss $ $ Condensed Consolidated Balance Sheets" |
|
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/02/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 03/02/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/01/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/01/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 9.8% stake in RHYTHM PHARMACEUTICALS, INC. |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 11.3% stake in Rhythm Pharmaceuticals, Inc. |
| 02/09/2023 |
SC 13G/A
| PRIMECAP MANAGEMENT CO reports a 12.3% stake in Rhythm Pharmaceuticals, Inc. |
| 02/09/2023 |
SC 13G/A
| JANUS HENDERSON GROUP PLC reports a 2.2% stake in RHYTHM PHARMACEUTICALS, INC. |
| 02/03/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/03/2023 |
SC 13G
| BlackRock Inc. reports a 6.6% stake in RHYTHM PHARMACEUTICALS INC |
| 02/01/2023 |
SC 13G/A
| FEDERATED HERMES, INC. reports a 11.2% stake in RHYTHM PHARMACEUTICALS, INC. |
| 01/09/2023 |
8-K
| Investor presentation |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/08/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
8-K
| Quarterly results |
| 10/07/2022 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 10.9% stake in Rhythm Pharmaceuticals, Inc. |
| 09/15/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/15/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 09/14/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/03/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/02/2022 |
8-K
| Quarterly results |
|